Compare ESTA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | KOD |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2018 | 2018 |
| Metric | ESTA | KOD |
|---|---|---|
| Price | $87.84 | $41.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $86.86 | $35.43 |
| AVG Volume (30 Days) | 767.0K | ★ 830.9K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,208,000.00 | N/A |
| Revenue This Year | $28.05 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $33.35 | $4.39 |
| 52 Week High | $92.84 | $47.84 |
| Indicator | ESTA | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 63.03 |
| Support Level | $63.71 | $39.37 |
| Resistance Level | N/A | $46.72 |
| Average True Range (ATR) | 3.84 | 3.05 |
| MACD | -0.46 | 0.67 |
| Stochastic Oscillator | 62.64 | 96.33 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.